Literature DB >> 15479312

A BIS-guided study of sevoflurane requirements for adequate depth of anaesthesia in Caesarean section.

K J Chin1, S W Yeo.   

Abstract

Caesarean section carries a high risk of awareness, especially in the period prior to neonatal delivery. We investigated the concentration of sevoflurane required to maintain bispectral index (BIS) < 60 until delivery occurred. We enrolled 23 parturients into an up-down sequential allocation study. The median effective end-tidal concentration (EC(50)) of sevoflurane was defined as that which maintained BIS < 60 between skin incision and delivery in 50% of patients. This was calculated using Dixon and Massey's method. Receiver operating characteristic curve analysis was used to establish BIS response probability thresholds. The EC(50) for sevoflurane was 1.22% (1.08-1.33, 95% CI). The probability of maintaining BIS < 60 was < 55% at a concentration of < 1.1%; this increased to 80% at concentrations of 1.2-1.3%. We conclude that sevoflurane concentrations of at least 1.2-1.3% should be administered in uncomplicated Caesarean section, so as to minimise the risk of awareness and recall.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15479312     DOI: 10.1111/j.1365-2044.2004.03944.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  10 in total

Review 1.  Using EEG to monitor anesthesia drug effects during surgery.

Authors:  Leslie C Jameson; Tod B Sloan
Journal:  J Clin Monit Comput       Date:  2006-12       Impact factor: 2.502

2.  Effect of decreased fetal perfusion on placental clearance of volatile anesthetics in a dual perfused human placental cotyledon model.

Authors:  Ryusuke Ueki; Tsuneo Tatara; Nobutaka Kariya; Noriko Shimode; Munetaka Hirose; Chikara Tashiro
Journal:  J Anesth       Date:  2014-01-03       Impact factor: 2.078

3.  Pulse perfusion value predicts eye opening after sevoflurane anaesthesia: an explorative study.

Authors:  Bruno Enekvist; Anders Johansson
Journal:  J Clin Monit Comput       Date:  2014-10-02       Impact factor: 2.502

4.  Neonatal effect of remifentanil in general anaesthesia for caesarean section: a randomized trial.

Authors:  Pavlina Noskova; Jan Blaha; Hana Bakhouche; Jana Kubatova; Jitka Ulrichova; Patricia Marusicova; Jan Smisek; Antonin Parizek; Ondrej Slanar; Pavel Michalek
Journal:  BMC Anesthesiol       Date:  2015-03-26       Impact factor: 2.217

5.  Evaluation of the adequacy of general anesthesia in cesarean section by bispectral index.

Authors:  Sayed Mohammad Reza Hadavi; Elaheh Allahyary; Saman Asadi
Journal:  Iran J Med Sci       Date:  2013-09

6.  Awareness and apgar score in elective Cesarean section under general anesthesia with propofol or Isoflurane: A prospective, randomized, double-blinded clinical trial study.

Authors:  Somayeh Khanjani; Khosrou Naghibi; Hamed Azarnoush
Journal:  Adv Biomed Res       Date:  2014-11-29

7.  Management of posterior reversible syndrome in preeclamptic women.

Authors:  S Poma; M P Delmonte; C Gigliuto; R Imberti; M Delmonte; A Arossa; G A Iotti
Journal:  Case Rep Obstet Gynecol       Date:  2014-11-19

8.  Role of potassium and calcium channels in sevoflurane-mediated vasodilation in the foeto-placental circulation.

Authors:  James Jarman; Chrisen H Maharaj; Brendan D Higgins; Rachel F Farragher; Christopher D Laffey; Noel M Flynn; John G Laffey
Journal:  BMC Anesthesiol       Date:  2009-06-10       Impact factor: 2.217

9.  The effects of hyperbaric or isobaric bupivacaine on bispectral index in spinal anesthesia for cesarean section.

Authors:  Mitra Jabalameli; Nina Hazegh; Saeed Gholami
Journal:  J Res Med Sci       Date:  2012-02       Impact factor: 1.852

10.  Bispectral index and cerebral oximetry in low-flow and high-flow rate anaesthesia during laparoscopic cholecystectomy - a randomized controlled trial.

Authors:  Jacek Kupisiak; Robert Goch; Wojciech Polenceusz; Robert Szyca; Krzysztof Leksowski
Journal:  Wideochir Inne Tech Maloinwazyjne       Date:  2011-12-20       Impact factor: 1.195

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.